Telephone sharing button Contact Us linkedin sharing button LinkedIn mailbox sharing button wuxixdc_info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

药明合联2023年业绩表现强劲,营收高速增长114%, 卓越业绩铸就未来发展根基和优势

营业收入强劲增长114%至21.24 亿元人民币 经调整净利润强劲增长112%至4.12 亿元人民币 综合项目数升至 143 个 新签订50个综合项目 临床II期和III期项目数增至21个,包括 5 个生产工艺验证(PPQ) 项目,为未来潜在商业化增长铸就强大动力 储备订单增长 82%至 5.79 亿美元,为公司维持高速增长势头打下基础 “一站式”生产设施在无锡基地成功投入运营,同园区偶联生产布局高效提升产能和规模 成功在香港交易所主板上市,总募集资金 5.2 亿美元,获评「IFR 亚洲」评选“最佳IPO” 荣膺「World...

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan 31, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for...
Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?